Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder

Simple item page
dc.contributor.affiliationDepartamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City 11340, Mexico
dc.contributor.emailmlafont@ipn.mx (M.C.M.-L.); lkuriaki@inprf.gob.mx (L.P.)
dc.creatorMaldonado-García, José Luis
dc.creatorGarcía-Mena, Lissette Haydee
dc.creatorMendieta-Cabrera, Danelia
dc.creatorPérez-Sánchez, Gilberto
dc.creatorBecerril-Villanueva, Enrique
dc.creatorAlvarez-Herrera, Samantha
dc.creatorHomberg, Toni
dc.creatorVallejo-Castillo, Luis
dc.creatorPérez-Tapia, Sonia Mayra
dc.creatorMoreno-Lafont, Martha C.
dc.creatorOrtuño-Sahagún, Daniel
dc.creatorPavón, Lenin
dc.creator.identificadorhttps://orcid.org/0000-0003-2694-1290 (Maldonado-García, José Luis)
dc.creator.identificadorhttps://orcid.org/0009-0009-4817-3043 (García-Mena, Lissette Haydee)
dc.creator.identificadorhttps://orcid.org/0000-0003-3878-0631 (Pérez-Sánchez, Gilberto)
dc.creator.identificadorhttps://orcid.org/0000-0001-9747-885X (Alvarez-Herrera, Samantha)
dc.creator.identificadorhttps://orcid.org/0000-0002-9532-3472 (Vallejo-Castillo, Luis)
dc.creator.identificadorhttps://orcid.org/0000-0002-2818-8522 (Pérez-Tapia, Sonia Mayra)
dc.creator.identificadorhttps://orcid.org/0000-0003-2896-5819 (Moreno-Lafont, Martha C.)
dc.creator.identificadorhttps://orcid.org/0000-0002-7443-2514 (Ortuño-Sahagún, Daniel)
dc.creator.identificadorhttps://orcid.org/0000-0002-6067-6868 (Pavón, Lenin)
dc.date2024
dc.date.accessioned2026-06-18T21:00:14Z
dc.date.issued2024
dc.date.published2024
dc.descriptionMajor depressive disorder (MDD) is a mood disorder that has become a global health emergency according to the World Health Organization (WHO). It affects 280 million people worldwide and is a leading cause of disability and financial loss. Patients with MDD present immunoendocrine alterations like cortisol resistance and inflammation, which are associated with alterations in neurotransmitter metabolism. There are currently numerous therapeutic options for patients with MDD; however, some studies suggest a high rate of therapeutic failure. There are multiple hypotheses explaining the pathophysiological mechanisms of MDD, in which several systems are involved, including the neuroendocrine and immune systems. In recent years, inflammation has become an important target for the development of new therapeutic options. Extracellular monomeric ubiquitin (emUb) is a molecule that has been shown to have immunomodulatory properties through several mechanisms including cholinergic modulation and the generation of regulatory T cells. In this perspective article, we highlight the influence of the inflammatory response in MDD. In addition, we review and discuss the evidence for the use of emUb contained in Transferon as a concomitant treatment with selective serotonin reuptake inhibitors (SSRIs).
dc.formatPDF
dc.identifierJC14NC24
dc.identifier.doi10.3390/ph17070841
dc.identifier.eissn1424-8247
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.placeSuiza
dc.identifier.urihttps://repositorio.inprf.gob.mx/handle/123456789/118
dc.identifier.urihttps://doi.org/10.3390/ph17070841
dc.language.isoeng
dc.publisherMDPI
dc.relation17(7):841
dc.relation.jnabreviadoPHARMACEUTICALS (BASEL)
dc.relation.journalPharmaceuticals (Basel)
dc.rightsAcceso Cerrado
dc.subject.kwMajor depressive disorder
dc.subject.kwImmunomodulator
dc.subject.kwInflammation
dc.subject.kwExtracellular monomeric ubiquitin
dc.subject.kwTherapeutic options based in small proteins
dc.titleUse of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder
dc.typeArtículo

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista